Date: 2016-10-10
Type of
information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the European Society for Medical Oncology (ESMO) 2016 Congress
Company: Endocyte (USA - IN)
Product: EC1169
Action
mechanism:
- EC1169 is an investigational therapeutic small molecule drug conjugate (SMDC) constructed of a high affinity Prostate Specific Membrane Antigen (PSMA)-targeting ligand conjugated through a releasable linker system to a potent cytotoxic microtubule inhibitor, tubulysin B hydrazide (TubBH). The high affinity of EC1169 for PSMA allows for the active and specific delivery of TubBH to PSMA-expressing cancer cells, while minimizing exposure to normal cells. PSMA is known to be highly expressed on the majority of prostate cancers with limited expression on normal tissues.
- The PSMA-targeted companion imaging agent EC0652 is being co-developed to characterize whole body PSMA expression in real time, to identify patients most likely to benefit from EC1169 therapy.
Disease: metastatic castration-resistant prostate cancer (mCRPC)
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
Is
general: Yes